title: Urotensin II levels in patients with chronic kidney disease and kidney transplants.
abstract: OBJECTIVE
  Urotensin II is a potent vasoactive peptide that has been implicated in the pathophysiology of many diseases. There is no study reporting the role and level of this peptide in recipients of kidney transplant. So we aimed to study the plasma levels of urotensin II in this group of patients.
  
  
  METHODS
  Plasma urotensin II levels were analyzed in 110 subjects, who were divided into three groups: group 1 (35 kidney transplant recipients), group 2 (36 patients with chronic kidney disease), and group 3 (39 healthy controls).
  
  
  RESULTS
  Analysis of logarithmic transformation of urotensin II, i.e. log (urotensin II × 1000) levels, with a one-way analysis of variance yielded a P value of 0.001. Post-hoc analysis showed significantly higher log (urotensin II × 1000) levels in group 1 than groups 2 and 3 (P = 0.001 and 0.017, respectively). One of the important features of the subjects of this group was that they were taking immunosuppressive drugs because of renal transplantation.
  
  
  CONCLUSIONS
  High urotensin II levels in recipients of kidney transplants could be drug-related (immunosuppressive drugs) and may be of practical importance that may be used to improve the long-term outcome of the patients.
authors.affiliation: Internal Medicine Department, VakIf Gureba Training & Research Hospital, Fatih, Istanbul, Turkey. hursitoglum@yahoo.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Hursitoglu
authors.forename: Tufan
authors.initials: T
authors.lastname: Tukek
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Cikrikcioglu
authors.forename: Osman
authors.initials: O
authors.lastname: Kara
authors.forename: Rumeyza
authors.initials: R
authors.lastname: Kazancioglu
authors.forename: Oktay
authors.initials: O
authors.lastname: Ozkan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cakirca
authors.forename: Fatih
authors.initials: F
authors.lastname: Akdogan
authors.forename: Erdal
authors.initials: E
authors.lastname: Gundogan
authors.forename: Sengul
authors.initials: S
authors.lastname: Aydin
authors.forename: Ismet
authors.initials: I
authors.lastname: Beycan
authors.forename: Meltem
authors.initials: M
authors.lastname: Gursu
authors.forename: Serkan
authors.initials: S
authors.lastname: Dogan
authors.forename: Aybala
authors.initials: A
authors.lastname: Erek
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D014579:Urotensins / Q000097:blood*
chemical_list: D007166:Immunosuppressive Agents; D014579:Urotensins; C029677:urotensin II
references.citation: Nephrol Dial Transplant. 2011 Feb;26(2):609-14
references.pmid: 20621933
references.citation: Curr Med Chem. 2009;16(5):550-63
references.pmid: 19199921
references.citation: Am J Physiol Renal Physiol. 2007 Jul;293(1):F2-9
references.pmid: 17429034
references.citation: Br J Pharmacol. 2006 Aug;148(7):884-901
references.pmid: 16783414
references.citation: Curr Opin Nephrol Hypertens. 2008 Mar;17(2):199-204
references.pmid: 18277155
references.citation: Nephrol Dial Transplant. 2003 Nov;18(11):2262-8
references.pmid: 14551352
references.citation: J Anesth. 2007;21(3):378-89
references.pmid: 17680191
references.citation: J Endocrinol. 2008 Sep;198(3):617-24
references.pmid: 18577565
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: Kidney Int. 2006 Aug;70(4):624-9
references.pmid: 16807543
references.citation: Anesth Analg. 2008 Jul;107(1):239-49
references.pmid: 18635495
references.citation: Am J Transplant. 2009 Nov;9 Suppl 3:S1-155
references.pmid: 19845597
references.citation: Int J Cardiol. 2004 Mar;94(1):93-7
references.pmid: 14996481
references.citation: Kidney Int. 2010 Jun;77(12):1055-7
references.pmid: 20508662
references.citation: Circulation. 2002 Dec 3;106(23):2877-80
references.pmid: 12460864
references.citation: Eur J Pharmacol. 2002 Mar 8;438(3):159-70
references.pmid: 11909607
references.citation: J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S7-11
references.pmid: 11347860
references.citation: Kidney Int. 2007 Mar;71(5):442-7
references.pmid: 17228366
references.citation: J Am Soc Hypertens. 2008 Sep-Oct;2(5):349-54
references.pmid: 18958182
references.citation: Peptides. 2008 May;29(5):859-67
references.pmid: 17610998
references.citation: Ethn Dis. 2009 Spring;19(2 Suppl 2):S2-1-7
references.pmid: 19537240
references.citation: Peptides. 2009 Feb;30(2):400-8
references.pmid: 18955095
references.citation: Nephrol Dial Transplant. 2007 Apr;22(4):1269-70
references.pmid: 17132703
references.citation: Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1147-50
references.pmid: 18505448
references.citation: Clin Transplant. 1999 Apr;13(2):181-6
references.pmid: 10202615
references.citation: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
references.pmid: 11904577
references.citation: Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1234-42
references.pmid: 18796544
references.citation: Peptides. 2009 Aug;30(8):1575-85
references.pmid: 19477209